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Abstract
 
Erythropoietin (rHuEPO) has proven to be effective in the
treatment of anemia of chronic renal failure (CRF). Despite
improving the quality of life, peak oxygen uptake after
rHuEPO therapy is not improved as much as the increase in
hemoglobin concentration ([Hb]) would predict. We hy-
pothesized that this discrepancy is due to failure of O
 
2
 
transport rates to rise in a manner proportional to [Hb]. To
test this, eight patients with CRF undergoing regular hemo-
dialysis were studied pre- and post-rHuEPO ([Hb] 
 
5
 
 7.5
 
6
 
1.0
vs. 12.5
 
6
 
1.0 g · dl
 
2
 
1
 
) using a standard incremental cycle ex-
ercise protocol. A group of 12 healthy sedentary subjects of
similar age and anthropometric characteristics served as
controls. Arterial and femoral venous blood gas data were
obtained and coupled with simultaneous measurements of
femoral venous blood flow ( leg) by thermodilution to ob-
tain O
 
2
 
 delivery and oxygen uptake ( O
 
2
 
). Despite a 69%
increase in [Hb], peak O
 
2
 
 increased by only 33%. This
could be explained largely by reduced peak leg blood flow,
limiting the gain in O
 
2
 
 delivery to 37%. At peak O
 
2
 
, after
rHuEPO, O
 
2
 
 supply limitation of maximal O
 
2
 
 was found
to occur, permitting the calculation of a value for muscle O
 
2
 
conductance from capillary to mitochondria (DO
 
2
 
). While
DO
 
2
 
 was slightly improved after rHuEPO, it was only 67%
of that of sedentary control subjects. This kept maximal ox-
ygen extraction at only 70%. Two important conclusions
can be reached from this study. First, the increase in [Hb]
produced by rHuEPO is accompanied by a significant re-
duction in peak blood flow to exercising muscle, which lim-
its the gain in oxygen transport. Second, even after restora-
tion of [Hb], O
 
2
 
 conductance from the muscle capillary to
the mitochondria remains considerably below normal. (
 
J.
Clin. Invest.
 
 1996. 97:2092–2100.). Key words: exercise 
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Introduction
 
Anemia is a prominent complication of chronic renal failure
(CRF)
 
1
 
 that requires treatment in a significant number of pa-
tients undergoing hemodialysis (1, 2). Since the late 80’s, the
therapy with recombinant human erythropoietin (rHuEPO)
has effectively eliminated the need for red cell transfusions
(1–4), thus avoiding commonly associated complications such
as infections and iron overload. Patients receiving rHuEPO
significantly improve their quality of life, but they exhibit a
higher incidence of hypertension seemingly associated with the
rHuEPO dosage (5).
Physiological studies on the long-term cardiorespiratory ef-
fects of rHuEPO treatment suggest that the increase in hemo-
globin concentration results in a suppression of the hyperdy-
namic cardiac state of these patients together with a modest
improvement of the aerobic exercise performance (6–13).
However, the effects of increased arterial O
 
2
 
 content (CaO
 
2
 
)
on muscle O
 
2
 
 use are not clear in CRF patients, and some of
them fail to significantly improve aerobic exercise capacity af-
ter rHuEPO, despite near normalization of hemoglobin con-
centration ([Hb]) (14). This limited exercise response could be
explained by one or more of the following factors: (
 
a
 
) gains in
muscle O
 
2
 
 delivery, calculated as the product of arterial O
 
2
 
content and muscle blood flow, could be less than expected;
(
 
b
 
) muscle O
 
2
 
 conductance from the muscle microcirculation
to the mitochondria may be abnormally low, reducing the ef-
fect of increased O
 
2
 
 delivery; or (
 
c
 
) oxygen uptake ( O
 
2
 
) may
not be O
 
2
 
 supply limited, such that enzyme or substrate limita-
tion would play the key role in determining O
 
2
 
max.
The current study was undertaken to assess the role of each
of the above-mentioned mechanisms in eight sedentary young
previously anemic, erythropoietin-treated patients with chronic
renal failure undergoing regular hemodialysis. All performed
maximum exercise on a bicycle ergometer at two different
inspired O
 
2
 
 concentrations (F
 
I
 
O
 
2
 
), both before and after
rHuEPO therapy to assess O
 
2
 
 supply-dependence of peak
O
 
2
 
. Data from 12 matched healthy young sedentary subjects
from a previous study (15) following a similar protocol were
used as control values. In all subjects, whole-body O
 
2
 
, O
 
2
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1. 
 
Abbreviations used in this paper:
 
 CaO
 
2
 
, arterial O
 
2
 
 content; C
 
fv
 
O
 
2
 
femoral venous O
 
2
 
 content; CRF, chronic renal failure; DO
 
2
 
, muscle
O
 
2
 
 conductance from the capillary to the mitochondria; F
 
I
 
O
 
2
 
, inspired
O
 
2
 
 concentration; [Hb], hemoglobin concentration; La
 
fv
 
, lactate levels
in femoral venous blood; leg, one-leg femoral venous blood flow;
O
 
2
 
leg, one-leg O
 
2
 
 delivery; RER, respiratory exchange ratio;
rHuEPO, recombinant human erythropoietin; 
 
E
 
, minute ventila-
tion; O
 
2
 
, whole-body O
 
2
 
 uptake; O
 
2
 
leg, one-leg O
 
2
 
 uptake.
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of one leg, and the convective and diffusive components of
muscle O
 
2
 
 transport (16) were assessed.
 
Methods
 
Population.
 
Eight sedentary anemic men (age 24
 
6
 
4.5 [mean
 
6
 
SD]
yr; height 169
 
6
 
5 cm; and wt 67
 
6
 
10 kg) with chronic renal failure un-
dergoing regular hemodialysis over the preceding 12
 
6
 
18 mo, were
enrolled in the study. Anthropometric, lung function data, adequacy
of dialysis, and [Hb] before and after rHuEPO therapy using stan-
dard dosage (92.5
 
6
 
21 UI · kg
 
2
 
1
 
 · week
 
2
 
1
 
) are listed in Table I. All
were informed of any risks and discomfort associated with the experi-
ment and informed consent was obtained in accordance with the
Committee on Investigations Involving Human Subjects at the Hos-
pital Clínic, Universitat de Barcelona. Subject preparation, safety
precautions, and technical aspects of the central measurements (arte-
rial and femoral venous blood gases and femoral venous blood flow)
have been described in detail elsewhere (15, 18).
Data from twelve healthy sedentary subjects, (11 males, 1 female)
(age 22
 
6
 
3.2 y; height 174
 
6
 
8 cm; and wt 71
 
6
 
10 kg; hemoglobin con-
centration 13.8 g · dl
 
2
 
1
 
) selected on the basis of no previous history of
regular or even occasional physical exercise above that required for
average daily activities, were used as control values. These data have
been previously reported (15).
 
Preliminary measurements.
 
Initially, each subject performed a
standard noninvasive incremental cycle exercise test (20-Watt incre-
ments every 2 min) until exhaustion. This test, which was carried out
breathing room air, served to determine maximal exercise capacity
(cycloergometer; E. Jaeger, Würzburg, Germany).
 
Principal studies.
 
On a single day, each renal failure patient per-
formed two similar exercise tests to exhaustion. The only difference
between each test was inspired O
 
2
 
 concentration (F
 
I
 
O
 
2
 
). This series of
two tests was carried out twice, once before and once after rHuEPO.
In the pre-rHuEPO study, the F
 
I
 
O
 
2
 
 values were 0.21 in one test and
1.0 in the other, whereas in the post-rHuEPO study, the correspond-
ing F
 
I
 
O
 
2
 
’s were 0.13 and 0.21. The order of presentation of the 2 in-
spirates was randomized but was identical for each patient in the pre-
and post-rHuEPO studies. Between the two exercise runs, the subject
rested for fully 1 h to ensure an adequate recovery. A target work-
load for each test was defined as the maximum workload sustained
for 2 min in the preliminary noninvasive study. However, an addi-
tional 20 W increment was tried to ensure that maximum exercise ca-
pacity had in fact been reached in each condition. The same level of
daily physical activity (as before rHuEPO) was maintained through-
out the period of the study despite the improvement in their quality
of life, as assessed using a physical activity questionnaire. Pre- and
post-rHuEPO studies in all the patients were done between 18 and
24 h after hemodialysis treatment (Table I). The time elapsed be-
tween pre- and post-rHuEPO studies was 7
 
6
 
5 mo.
On-line calculations of whole body O
 
2
 
, CO
 
2
 
 output ( CO
 
2
 
),
minute ventilation (
 
E
 
), respiratory exchange ratio (RER), heart
rate, and respiratory rate were averaged sequentially over 15-s inter-
vals and displayed on a screen monitor to observe the progress of the
tests and confirm a steady state for O
 
2
 
. In each test, in the eight
CRF patients in the pre- and post-rHuEPO studies, measurements
were made under the following conditions: (
 
a
 
) at rest; (
 
b
 
) during sub-
maximal workloads (30, 60, and 80% of peak workload); and (
 
c
 
) at
maximum workload. In the 12 healthy sedentary subjects measure-
ments were done only: (
 
a
 
) at rest; (
 
b
 
) at 60% of maximum workload;
and (
 
c
 
) at maximum workload (15). In each instance the following
measurements were made: (
 
a
 
) PO
 
2
 
, PCO
 
2
 
, pH (IL model 1302, pH/
Blood gas analyzer and tonometer model 237. Instrumentation Labo-
ratories, Milan, Italy), oxyhemoglobin saturation, [Hb] (IL 482
co-oximeter; Instrumentation Laboratories), and blood lactate con-
centrations (YSI 23L blood lactate analyzer; Yellow Springs Instru-
ments, Yellow Springs, OH) from simultaneous arterial and femoral
venous blood samples; and (
 
b
 
) femoral venous blood flow ( leg) and
arterial pressure. As indicated above, 
 
E
 
, F
 
E
 
O
 
2
 
, F
 
E
 
CO
 
2
 
, and HR
were continuously monitored. Technical aspects of these measure-
ments have been previously provided in detail (15).
In the present study, blood O
 
2
 
 content was calculated as follows:
[(1.39 · [
 
Hb
 
] · 
 
measured oxyhemoglobin saturation
 
) 
 
1
 
 (0.003 · PO
 
2
 
)].
This was done for arterial (CaO
 
2
 
) as well as venous (C
 
fv
 
O
 
2
 
) blood.
The O
 
2
 
 delivery to the exercising leg ( O
 
2
 
leg) was calculated as the
product of arterial O
 
2
 
 content and leg blood flow [
 
O
 
2
 
leg
 
 
 
5
 
 
 
C
 
a
 
O
 
2
 
 
 
·
 
leg
 
]. Leg O
 
2
 
 uptake ( O
 
2
 
leg) was obtained as the product of Qleg
and the arterial 
 
2
 
 femoral venous difference of O
 
2 content [ O2leg
5 leg · (CaO2 2 CfvO2)]. Leg O2 extraction ratio (O2ER) was calcu-
lated as the ratio of the arterial to femoral venous O2 content differ-
ence and the arterial O2 content [O2ER 5 100.(CaO2 2 CfvO2)/CaO2].
Net lactate output across the leg ( ) was obtained as the product be-
tween leg and the femoral venous to arterial difference in blood lac-
tate concentrations ( 5 leg · (Lafv 2 Laa)]. In each subject, mea-
V
.
V
.
V
.
V
.
Q
.
V
.
Q
.
Q
.
Q
.
V
.
V
.
Q
.
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.
Q
.
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.
Q
.
Table I. Anthropometric Data, Lung Function, Adequacy of Dialysis, and Changes in Hemoglobin Concentration
Subject Age Height Weight FEV1 FEV1/FVC PaO2 Kt/V PCR HD Dialyzer [Hb] [Hb] D[Hb]
yr cm kg liters %pred % mmHg urea g?k21?d h?wk21 pre-rHuEPO post-rHuEPO g?dl21
MNP 20 176 62 4.9 (109) 81 101 1.1 0.9 12 C 1.5 9.2 12.5 3.3
RCS 20 167 58 4.6 (114) 87 109 1.2 1.1 12 C 1.3 7.3 12.5 5.2
VLL 21 166 65 4.6 (114) 87 101 1.1 1.0 12 CA 1.4 7.7 11.0 3.3
JRM 20 172 58 4.3 (99) 93 116 1.0 0.9 10.5 C 1.3 8.5 11.0 2.5
MMB 29 165 80 3.5 (92) 88 113 1.2 1.2 12 CA 1.4 7.5 12.3 4.8
JGG 21 167 83 3.8 (95) 87 87 1.0 1.0 12 C 1.5 7.7 14.2 6.5
FMM 29 172 70 3.6 (85) 81 100 1.3 1.2 12 C 1.7 6.5 13.8 7.3
JMR 29 169 63 2.9 (73) 79 111 1.2 1.1 13.5 C 1.5 5.9 12.7 6.8
Mean 24 169 67 4.0 (98) 85 105 1.1 1.1 12 7.5 12.5 5.0
SD 5 5 10 0.7 15 4 9 0.1 0.1 0.8 1.0 1.0 1.8
Results expressed as mean6SD; FEV1, forced expiratory volume in the first second in liters and as percentage of predicted value within parentheses
(17); FEV1/FVC, FEV1 to forced vital capacity ratio; PaO2, PO2 in arterial blood; Kt/V(urea), indicates the decrease of BUN during each dialysis
treatment, dimensionless; PCR, protein catabolic rate expressed in g · k21 · d; HD, duration of dialysis in h · wk21 (three times a wk); Dialyzer, type of
membrane of the dialyzer and surface expressed in square meters: C 1.5, Cuprophane 1.5 m2, CA 1.4, Cellulose Acetate 1.4 m2; [Hb] pre-rHuEPO and
[Hb] post-rHuEPO, hemoglobin concentration in the pre-rHuEPO and post-rHuEPO studies expressed in g · dl21, respectively; D[Hb], increase in
[Hb] after rHuEPO therapy.
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sured O2 saturation and the corresponding PO2 from all samples were
used to estimate the P50 of hemoglobin. Calculations of mean muscle
capillary PO2 (PmcO2) and the corresponding value of muscle O2 con-
ductance (DO2) were obtained by numerical integration (16, 19–22);
the assumptions involved in this analysis having been previously de-
scribed in detail (16). It should be noted that DO2 is a lumped param-
eter that reflects both diffusional conductance and the effect of any
heterogeneity of VO2 with respect to blood flow. The O2 conductance
from the microcirculation to the muscle cell (DO2) was calculated at
peak exercise from: (a) the room air measurement in the pre-
rHuEPO study; (b) the data of both the hypoxic and room air mea-
surements (FIO2 of 0.13 and 0.21) in the post-rHuEPO study; and (c)
the data of both the hypoxic measurements (FIO2 of 0.12 and 0.15) in
the control group. Maximum O2 uptake data breathing room air (con-
trol subjects) and 100% O2 (pre-rHuEPO study) were not used to es-
timate DO2 because they did not fulfill the requirements of the analy-
sis, as discussed above and in (15).
Data analysis. Results are expressed as mean6SD. After rHuEPO,
changes in leg were compared using an analysis of covariance after
demonstrating existence of a linear relationship between leg and
whole-body O2 (as work rate was increased) with no variations in
the slope from pre- to post-rHuEPO. For the remaining variables in
the study, results during submaximal exercise were examined pooling
the data obtained at 30, 60, and at 80% of peak work load. Compari-
sons between pre- and post-rHuEPO studies were done using the
Student’s paired t test, and those between post-rHuEPO and the con-
trol group of healthy sedentary subjects were carried out using the
Student’s unpaired t test. Pearson’s regression analysis was used to
Q
.
Q
.
V
.
Table II. Whole-body Variables during Submaximal and Peak Exercise, FIO2 5 0.21
Rest 30% W 60% W 80% W 100% W P pre-post P post-con
Watts Pre-rHuEPO 0  4168  83618 111623 134626 NS 0.0001
Post-rHuEPO 0  40611  90619 120615 145620
Control 0  6468 115615 170621 216634
O2 Pre-rHuEPO 0.3460.06 0.9860.07 1.2660.23 1.5160.23 1.6960.28 0.001 0.03
liters · min21 Post-rHuEPO 0.3560.05 1.0260.15 1.4660.35 1.7660.24 2.1860.33
Control 0.3260.07 1.0560.22 1.7460.22 2.1860.28 2.6660.48
O2 Pre-rHuEPO 4.662.0 14.761.8 19.164.4 22.663.4 25.464.6 0.003 NS
ml · kg21 · min21 Post-rHuEPO 5.360.8 15.561.4 21.963.6 26.762.1 33.164.7
Control 4.461.4 14.662.7 24.362.9 30.463.9 36.965.9
CO2 Pre-rHuEPO 0.3060.06 0.8960.11 1.4060.22 1.8560.29 2.2160.33 0.01 0.03
liters · min21 Post-rHuEPO 0.3160.06 0.8660.12 1.4860.33 1.9660.28 2.6260.33
Control 0.2960.06 0.9660.28 1.8060.20 2.5260.31 3.5160.63
RER Pre-rHuEPO 0.8960.07 0.9160.11 1.1160.06 1.2360.06 1.3260.08 NS NS
Post-rHuEPO 0.8860.09 0.8460.09 1.0260.11 1.1260.12 1.2160.13
Control 0.9260.13 0.9160.15 1.0460.07 1.1660.10 1.3060.09
E Pre-rHuEPO  1062.4  2866.7  4064.3  5568.2  77611.7 NS 0.01
liters · min21 Post-rHuEPO  1162.1  2565.7  4068.9  5568.7  83610.7
Control  1162.8  26610  4766.6  63614 115627.5
HR Pre-rHuEPO  88611 116616 130624 146621 157616 NS 0.03
min21 Post-rHuEPO  85620 109617 132623 148624 162615
Control  99611 116617 147611 164615 176612
Results expressed as mean6SD; 30, 60, 80, and 100% W correspond to measurements carried out at those percentages of peak exercise workload;
Pre-rHuEPO, Post-rHuEPO, and Control, results before rHuEPO therapy, Post-rHuEPO therapy, and from the sedentary control subjects respec-
tively; O2, O2 uptake; CO2, CO2 production; RER, respiratory exchange ratio; E, minute ventilation (BTPS); HR, heart rate; pre-post, probabil-
ity of the comparisons between pre- and post-rHuEPO measurements at peak exercise (paired analysis); post-con, probability of the comparisons be-
tween post-rHuEPO study and sedentary control subjects at peak exercise (unpaired analysis).
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Figure 1. Relationships between whole-body O2 uptake and external 
work rate. pre-rHuEPO, prior to erythropoietin; post-rHuEPO, after 
erythropoietin therapy; control, healthy sedentary subjects. The cal-
culated mechanical efficiency in the overall set of measurements was 
26.8%. Results are expressed as mean6SEM.
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explore the relationships between variables. Statistical significance
was set at P # 0.05.
Results
After the rHuEPO therapy, [Hb] in the eight renal patients in-
creased by 5.061.8 g · dl21, from 7.561.0–12.561.0 g · dl21 (Ta-
ble I). All patients had normal arterial blood gases both at rest
and at all exercise workloads, as exemplified by the alveolar-
arterial O2 difference (at peak exercise, 568.3 and 369.0
mmHg, pre- and post-rHuEPO, respectively). Consequently,
at rest, the 69% increase in [Hb] (mean of individual re-
sponses) after rHuEPO therapy resulted in a similar (59%) ar-
terial O2 content change of 6.262.4 ml O2 · 100 ml21, from
10.861.6–17.061.4 ml O2 · 100 ml21. Similar values were ob-
served during exercise.
Exercise performance. Exercise data from the patients
(pre- and post-rHuEPO) and from the sedentary control sub-
jects are shown in Tables II and III and in Fig. 1–3. Although a
plateau in whole-body O2 at peak workload could not be
clearly defined in most of the patients, the respiratory ex-
change ratio (from 1.21 to 1.30) and the elevated blood lactate
levels obtained at peak workload suggest that maximal exer-
cise was achieved in both pre- and post-rHuEPO studies. After
rHuEPO, peak whole-body O2 increased 30% by 0.4960.25
liters · min21 but was still lower (P 5 0.03) than that observed
in the control group (33.164.7 ml · kg21 · min21, CRF post-
rHuEPO, and 36.965.9 ml · kg21 · min21, normal subjects). As
shown in Fig. 1, the patients (pre- and post-rHuEPO) and the
control subjects showed a similar linear relationship between
whole-body VO2 and external work.
After rHuEPO therapy (Fig. 2), at any given oxygen up-
take, E, RER, and femoral venous blood lactate levels (Lafv)
were consistently lower. In the post-rHuEPO study, the rela-
tionships between these variables and whole-body O2 were
similar to those of sedentary control subjects, but maximal val-
ues of O2, E, and Lafv were less than in control subjects. In
contrast, at any given oxygen uptake, no significant changes
were observed in the net lactate output across the leg between
the patients (both pre- and post-rHuEPO) and the control
group.
One-leg blood flow and O2 delivery. Femoral venous blood
flow ( leg) was consistently reduced after rHuEPO (P ,
0.004). On average, leg decreased by 0.7060.9 liters · min21
V
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Figure 2. Relationships between whole-body O2 uptake and, from 
top to bottom, minute ventilation ( E), respiratory exchange ratio, 
and femoral venous lactate concentration (Lafv). At any given O2, 
E, RER, and Lafv decreased after rHuEPO. No differences were 
found between submaximal exercise data of the post-rHuEPO study 
and those of the sedentary control group. Results are expressed as 
mean6SEM.
V
.
V
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V
.
Figure 3. Relationships between femoral venous blood flow and 
whole-body O2 uptake. At any given O2, leg significantly de-
creased after rHuEPO (P , 0.004). No differences were detected be-
tween the post-rHuEPO and control group. Results are expressed as 
mean6SEM.
V
.
Q
.
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(Fig. 3 and Table III), a fall of 13% at peak exercise compared
to before rHuEPO. This reduction in leg partially offset the
effect of the rHuEPO-induced increase in arterial O2 content
of O2 delivery ( O2leg). Consequently, the increase in O2leg
after rHuEPO at peak exercise was only 0.2260.25 liters ·
min21 (37%).
One-leg O2 uptake. As shown in Table III, leg O2 signifi-
cantly increased after rHuEPO at each relative workload (P 5
0.05). This was because a given relative work load occurred at
a higher absolute level post-rHuEPO. At peak exercise, post-
rHuEPO O2leg rose by 0.1360.13 liters · min21 (33%) (P 5
Q
.
Q
.
Q
.
V
.
V
.
0.03) but was still 18% lower than that observed in the control
group (8.561.6 compared to 1062.7 ml · kg21 · min21, respec-
tively).
Femoral venous PO2 and O2 extraction. At peak exercise,
no significant changes were observed in femoral venous PO2
(PfvO2) (2462.7 mmHg pre-rHuEPO vs. 2765.4 mmHg post
rHuEPO), femoral venous O2 saturation (28.666.8 vs.
27.969.0%) or in O2 extraction ratio (O2ER) at peak exercise
after rHuEPO (from 7166 to 70610%, respectively). Post-
rHuEPO O2ER was similar to that observed in the control
group (7268%).
Table III. O2 Transport Variables during Submaximal and Peak Exercise, FIO2 5 0.21
Rest 30% W 60% W 80% W 100% W P pre-post P post-con
PaO2 Pre-rHuEPO 10569 109611 113611 11568 11869 NS NS
mmHg Post-rHuEPO 10669 109611 11068 115610 116610
Control  96610 — 10467 — 11568
PaCO2 Pre-rHuEPO  3664 3564  3664  3464  3065 NS NS
mmHg Post-rHuEPO  3361 3763  3763  3664  3262
Control  3563 —  3863 —  3163
CaO2 Pre-rHuEPO 10.861.9 10.761.4 10.661.4 10.861.6 11.061.7 0.0002 0.01
ml · 100ml21 Post-rHuEPO 17.061.3 17.061.4 17.061.5 17.061.5 17.061.4
Control 18.961.4 — 19.261.3 — 19.261.4
PfvO2 Pre-rHuEPO  2766.8  2463.5 2463.4  2462.9  2462.7 NS NS
mmHg Post-rHuEPO  2765.2  2464.8 2665.0  2765.5  2765.4
Control  2565.3 — 2361.7 —  2564.3
PfvCO2 Pre-rHuEPO  4265.5  5065.7  5365.1  5564.6  5365.4 0.005 NS
mmHg Post-rHuEPO  4265.5  5765.0  6265.3  6266.3  6367.6
Control  4564.1 —  6065.0 —  6565.1
CfvO2 Pre-rHuEPO 4.961.6 3.660.7 3.660.9 3.460.7 3.265.1 0.01 NS
ml · 100ml21 Post-rHuEPO 8.262.5 5.761.7 5.761.9 5.662.1 5.161.8
Control 8.663.3 — 6.061.0 — 5.461.7
leg Pre-rHuEPO — 3.260.5 4.160.9 4.960.8 5.661.1 0.004 NS
liters · min21 Post-rHuEPO — 2.461.1 3.461.4 4.461.5 4.961.5
Control — — 4.260.7 — 5.160.8
O2leg Pre-rHuEPO — 0.3560.07 0.4360.08 0.5260.09 0.6160.12 0.04 0.04
liters · min21 Post-rHuEPO — 0.4060.20 0.5760.08 0.7460.27 0.8360.28
Control — — 0.8060.15 — 0.9860.14
O2 ER Pre-rHuEPO  53618  6668  6668  6867  7166 NS NS
liters · min21 Post-rHuEPO  52613  67610  67610  67611  70610
% Control  55615 — 6964 —  7268
O2leg Pre-rHuEPO — 0.2360.06 0.2860.07 0.3660.08 0.4460.11 0.03 0.04
liters · min21 Post-rHuEPO — 0.2660.1 0.3760.15 0.4860.15 0.5760.15
Control — — 0.5660.10 — 0.7160.13
Pre-rHuEPO — 1.761.4 1.861.8 2.261.8 4.462.7 NS NS
mM · min21 Post-rHuEPO — 1.161.6 3.063.3 2.362.0 3.963.1
Control — — 2.861.2 — 4.862.9
Results expressed as mean6SD; 30, 60, 80, and 100% W correspond to measurements carried out at those percentages of peak exercise workload;
Pre-rHuEPO, Post-rHuEPO, and Control, results before rHuEPO therapy, post-rHuEPO therapy, and from the sedentary control subjects respec-
tively; PaO2 and PaCO2, PO2 and PCO2 in arterial blood; CaO2, arterial O2 content; PfvO2, PfvCO2 and CfvO2, femoral venous PO2, PCO2 and O2
content; leg, femoral venous blood flow; O2leg, one-leg O2 delivery; O2 ER, muscle O2 extraction as a percentage; O2leg, one-leg O2 uptake; ,
lactate output across the leg; pre-post, probability of the comparisons between pre- and post-rHuEPO measurements at peak exercise (paired analy-
sis); post-con, probability of the comparisons between post-rHuEPO study and sedentary control subjects at peak exercise (unpaired analysis).
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DO2 at peak exercise. In the post-rHuEPO study, O2leg
and mean muscle capillary PO2 (or femoral venous PO2) at
maximum exercise determined during hypoxia and room air
followed a linear and proportional relationship. Hence, O2
supply dependency of peak O2 constitutes a reasonable as-
sumption, allowing calculation of O2 conductance, as analyzed
in Discussion. Such behavior was also observed in the studies
during hypoxia in the control group (15). The slopes of the
dashed lines in Fig. 4 reflect this proportionately, and hence in-
dicate the DO2 of each study group. Based on only the room
air data before rHuEPO in which O2 supply dependency had
been assumed, muscle O2 conductance increased by 31% after
erythropoietin, from 10.463.3 to 13.063.1 ml O2 · min21 ·
mmHg21 (P 5 0.02). However, the post-rHuEPO DO2 was
still 33% lower than that observed in healthy sedentary sub-
jects (19.465.4 ml O2 · min21 · mmHg21) (P 5 0.007). Most
(71%) of the change in muscle O2 conductance after rHuEPO
V
.
V
.
was explained by the concomitant changes in both hemoglobin
concentration and femoral venous blood flow (DDO2 5 0.75
D[Hb] 1 1.06 D leg, r2 5 0.71).
Discussion
Summary of principal findings. This study shows that after
erythropoietin therapy there is a substantial rise (69%) in he-
moglobin concentration, and thus in CaO2 (59%) in patients
with chronic renal failure, but at the same time a moderate but
consistent fall in femoral venous blood flow (of 13% at peak
O2 and even more submaximally) (Fig. 3). The latter is prob-
ably due to the reversal of the hyperhemodynamic state pro-
voked by the anemia (23, 24). The fall in leg partially offset
the increase in O2 delivery expected from the rise in arterial O2
content. Thus, O2leg rose by only 37%.
While rHuEPO enhanced aerobic capacity (whole-body
O2 by 30% and O2leg by 33%, respectively) (Figs. 2 and 3),
the relative change was much less than that of arterial O2 con-
tent (59%). This occurred despite increases in the two major
components of O2 transport from the atmosphere to the mus-
cle cell after rHuEPO: oxygen delivery (37%) and muscle O2
conductance (31%). The relative contributions of these two
components of O2 transport can explain the differences be-
tween the gains in O2 content and O2leg at peak exercise, as
discussed below.
Oxygen supply limitation of peak O2 was found to occur
after rHuEPO, as indicated in Fig. 4 and discussed below,
which allowed an estimate of muscle O2 conductance. It should
be noted that although DO2 increased 31% with erythropoi-
etin, post-rHuEPO DO2 was the most severely impaired index
of O2 transport (Fig. 5), being 33% less than that in activity-
matched control subjects.
Since 1990, several studies (5–13) have shown a rather
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Figure 4. Relationships of one-leg O2 uptake to mean muscle capil-
lary PO2 (top) and femoral venous PO2 (bottom). The inspired O2 
fraction (FIO2) of each measurement is indicated in the figure. 
Dashed lines indicate muscle O2 conductance of each study group.
Figure 5. Results of key muscle O2 transport variables expressed as 
percentages of the values obtained in the sedentary control subjects 
(discontinuous line). Dashed bars represent the pre-rHuEPO data 
and black bars correspond to the post-rHuEPO study. Values are 
mean6SEM. * Indicates statistical significance (P , 0.05) between 
pre- and post-rHuEPO results, and ‡ refers to the comparison be-
tween post-rHuEPO and control group(P , 0.05).
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small improvement in O2 peak after rHuEPO therapy de-
spite increases in [Hb] to almost normal levels, as confirmed in
the present study. Impairment of O2 transport to the mito-
chondria and/or alterations in the regulation of the oxidative
phosphorylation in the cell have been invoked as the two po-
tential explanations of the phenomenon, but no measurements
have been made to confirm or refute these suggestions. The
current study therefore represents the first integrative investi-
gation of the changes with rHuEPO in the factors determining
muscle O2 transport. Recently, Moore et al. (25) reported no
differences in cellular oxidative capacity (31-phosphorus nu-
clear magnetic resonance spectroscopy) among: (a) CRF pa-
tients under regular hemodialysis; (b) patients after renal
transplantation; and (c) control subjects, indirectly suggesting
impairment in O2 transport in the muscle microcirculation as
the primary explanation for the limited increase in O2peak
after rHuEPO. Dissociation between systemic hematocrit and
microvascular hematocrit (26) can be invoked as an additional
factor to explain the differences between gains in CaO2 and in
O2leg at peak exercise after rHuEPO therapy. However, this
possibility could not be ruled out since microvascular hemat-
ocrit cannot be measured during exercise in intact subjects.
Muscle biopsies done in CRF patients (27) indicate that many
muscle fibers show abnormally low adjacent capillary supply,
which would provide the structural bases for the low muscle O2
conductance obtained in our study. The results from the cur-
rent investigation support the contention that abnormal mus-
cle O2 transport is the key factor limiting increases in O2 in
anemic CRF patients after rHuEPO therapy.
Interactions between O2 delivery and muscle O2 conduc-
tance in the effects of rHuEPO. As proposed by Piiper and
Scheid (28), O2 extraction (under conditions of O2 supply limi-
tation of O2max) depends on the ratio of muscle O2 diffu-
sional conductance (DO2) to perfusional conductance (b ·
leg). The term b corresponds to the slope of the O2 dissocia-
tion curve and is the ratio of the arterial to femoral venous O2
content difference and the arterial to femoral venous PO2 dif-
ference [b 5 (CaO2 2 CfvO2)/(PaO2 2 PfvO2)]. The most effi-
cient way to improve O2 transfer to the mitochondria therefore
occurs in those circumstances that provide an increase in this
ratio. Endurance training for example, increases not only car-
diac function, and thus leg, but also DO2. Because DO2 in-
creases relatively more than does leg (15), DO2/b · leg in-
creases, raising maximal O2 extraction. Thus O2max
increases with training due to both increased leg blood flow
and increased O2 extraction (15).
In contrast, the patients with chronic renal failure of the
present study showed a fall in leg (13%), an increase in DO2
(31%), and an increase in [Hb] (69%) that raised b by 65%.
This led to no significant change in DO2/b · leg ratio (2.226
0.70 pre-rHuEPO vs. 2.1260.58 post-rHuEPO) explaining
how after rHuEPO, CRF patients do not exhibit any change in
muscle O2 extraction. Had DO2 not increased by 31%, DO2/b ·
leg would have fallen to z 1.7 and O2 extraction would have
fallen, further reducing the benefits of rHuEPO on O2peak.
DO2 probably increased due to the higher [Hb], consistent
with previous observations (29), although the specific mecha-
nism remains obscure.
Analysis of O2 supply limitation. The use of two levels of
FIO2 in the pre- and post-rHuEPO studies was adopted be-
cause the calculation of DO2 requires the demonstration of O2
supply dependence of peak O2 (16, 19, 21), and changing
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FIO2 is the most acceptable way to alter O2 transport in intact
subjects. Oxygen supply limitation would be manifest by a
higher O2peak at the higher FIO2. Moreover, one would ex-
pect the calculated DO2 at each FIO2 to be the same (21). This
is equivalent to demonstration of proportionality between
O2max and mean muscle capillary PO2 as FIO2 is varied. In
the post-rHuEPO studies (FIO2 5 0.13 and 0.21) this was in-
deed observed. However, before rHuEPO, it was not consid-
ered ethical to study these patients at any reduced FIO2 be-
cause of the anemia. Thus, we chose 100% O2 as the second
inspired gas. Because 100% O2 did not increase O2peak in
these patients, we were unable to confirm O2 supply depen-
dency of O2peak breathing room air before rHuEPO. We
have for comparison purposes assumed that O2peak at FIO2
5 0.21 is supply limited and computed the associated DO2 un-
der this condition. To the extent that even at FIO2 5 0.21 our
patients were not O2 supply limited at O2peak, this value of
DO2 would be an underestimate (15), such that the relative in-
crease in DO2 after rHuEPO would be overestimated.
As indicated in Fig. 4, conditions of O2 supply dependency
were satisfied in the post-rHuEPO study and in the hypoxic
measurements carried out in the control group. O2peak in-
creased with FIO2 in an amount that reflects the corresponding
increase in O2 delivery. However, the CRF patients were not
tested in the pre-rHuEPO study since the estimation of muscle
O2 conductance was done only during room air breathing. It
should be noted that the arterial O2 content before rHuEPO at
FIO2 5 0.21 was similar to that observed post-rHuEPO at an
FIO2 of 0.13 and in the healthy sedentary subjects at FIO2 5
0.12. Consequently, it can be reasonably argued that the CRF
patients were likely to be O2 supply dependent breathing room
air in the pre-rHuEPO study. However, if anything, pre-
rHuEPO O2 conductance at FIO2 5 0.21 would have been un-
derestimated if peak O2 breathing air were not O2 supply
limited (15), so that the calculated 31% change in DO2 is a
maximal value. It should be noted that up to 71% of the vari-
ance in DO2 (calculated assuming O2 supply dependence) was
explained by the concomitant changes in both hemoglobin
concentration and femoral venous flow.
Comparisons between the post-rHuEPO study and the con-
trol group (Fig. 5). Hemoglobin concentration and leg at
peak exercise after rHuEPO were slightly lower than in the
healthy sedentary subjects (29 and 24%, respectively). No
such difference was observed in arterial PO2, and consequently
the O2leg was 15% lower in the patients with CRF. How-
ever, muscle O2 conductance, among all variables determining
O2 transport, was the most severely impaired in the CRF pa-
tients. Even after rHuEPO, DO2 was 33% lower than that of
the control group, which was well matched for lack of exercise
and for age, height, and weight. The higher O2 delivery (15%)
and the higher DO2/b · leg ratio (8%) observed in the
healthy sedentary subjects together explain the higher O2leg
at maximum exercise (by 18%) of the control group compared
to the post-rHuEPO CRF patients.
The structural basis for the reduced muscle O2 conductance
was not examined in the present study since muscle biopsies
were not attempted, but it is likely to reflect a less rich muscle
microcirculatory network (27, 30, 31), since a previous study in
a dog model without renal disease (32) has highlighted capil-
lary surface area in muscle as the key structural factor that de-
termines O2 conductance. In contrast, the subsequent diffusion
distance to the mitochondria appears to offer little impediment
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to O2 transport, presumably due to diffusion facilitation by
myoglobin (33). The structural heterogeneity in the matching
of capillaries to muscle fibers observed in CRF patients (27)
suggests that functional heterogeneity of / O2 ratios may
constitute an additional factor to explain impairment of muscle
O2 transfer in these patients. Although limitation of aerobic
capacity in CRF patients is a complex phenomenon, the
present study provides the first direct evidence for impaired O2
transport out of the muscle microcirculation. This may explain,
in part, the subnormal levels of O2peak in chronic renal fail-
ure and the poor response to rHuEPO.
Possible exercise training during rHuEPO therapy. In the
current study, to preclude training occurring as a result of feel-
ing better after rHuEPO therapy, all CRF patients were re-
peatedly instructed to maintain the same level of daily physical
activity throughout the protocol. However, if any spontaneous
training effect had developed as a result of the improvement of
both quality of life and exercise tolerance, the end result would
have presumably been an increase in leg and muscle O2 con-
ductance. Thus, this would have decreased the differences be-
tween post-rHuEPO measurements and those obtained in the
sedentary control subjects. Consequently, the assertion of an
abnormally low O2 conductance even after [Hb] restoration is,
if anything, strengthened to the extent that any training took
place without our knowledge.
In summary, the hemodynamic response of reduced leg
blood flow to the increase in hemoglobin concentration pro-
duced by rHuEPO plays a key role in limiting the increase in
O2 uptake at peak exercise. Analysis of the interactions be-
tween the convective and diffusive components of muscle O2
transport shows an increased but still abnormally low muscle
O2 conductance after rHuEPO. However, the even greater net
increase in perfusional conductance for O2 due to the increase
in [Hb] contributes to the relatively limited increase in peak
O2 because it does not allow O2 extraction to increase. Mus-
cle O2 transport conductance in CRF, even after rHuEPO, is
z 33% lower than that in control subjects (matched for age,
size, and activity). This suggests a myopathic alteration, possi-
bly of the microcirculation, due to renal failure that compro-
mises exercise capacity more than anemia and inactivity alone
would predict.
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